GO
Loading...

Merck & Co Inc

More

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Gilead drags healthcare shares down on drug price worries Wednesday, 4 Feb 2015 | 11:38 AM ET

    Feb 4- Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure. Gilead weighed most heavily on the biotechnology sector with a 8.9 percent drop in its...

  • Merck's hep C drugs to lose breakthrough status Wednesday, 4 Feb 2015 | 9:19 AM ET
    Scientist Kate Lipford evaporates solvents in the research lab at Merck in the Longwood medical district.

    Merck said the U.S. FDA intends to rescind its "breakthrough" designation for its experimental combination treatment for hep C.

  • US firms disavow their global reach: Jack Welch Wednesday, 4 Feb 2015 | 8:55 AM ET
    Jack Welch

    U.S. companies no longer want to be associated with big global operations because of the dollar, Jack Welch tells CNBC.

  • Wall Street eyes oil as rebound fades Wednesday, 4 Feb 2015 | 8:54 AM ET

    U.S. stock index futures are signalling a lower open on Wall Street on Wednesday, as a tentative rebound in oil prices fades.

  • GSK sales falls; firm upbeat on respiratory unit Wednesday, 4 Feb 2015 | 8:45 AM ET

    Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.

  • Merck reports mixed results   Wednesday, 4 Feb 2015 | 8:23 AM ET
    Merck reports mixed results

    Barbara Ryan, Clermont Partners, digs in on Merck's earnings and provides insight to cancer drugs in Merck's pipeline.

  • Early movers: ODP, SPLS, GM, MRK, ADP & more Wednesday, 4 Feb 2015 | 8:06 AM ET
    A trader works on the floor of the New York Stock Exchange, Oct. 31, 2014.

    Some of the names on the move ahead of the open.

  • Wall Street watches oil as rebound fades Wednesday, 4 Feb 2015 | 5:59 AM ET

    U.S. stock index futures are signalling a lower open on Wall Street on Wednesday, as a tentative rebound in oil prices fades.

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • Early movers: LE, SYY, WYN, JCP, M, GM & more Monday, 2 Feb 2015 | 7:55 AM ET
    NYSE New York Stock Exchange traders markets

    Some of the names on the move ahead of the open.

  • Feb 2- At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows. The companies, all members of the S&P 500, and including some of the biggest names in Corporate America such as autos giant General Motors and drug maker...

  • WASHINGTON, Feb 1- President Barack Obama's fiscal 2016 budget proposes a 19 percent tax on U.S. companies future foreign earnings and a one-time 14 percent tax on roughly $2 trillion of profits being held offshore, the White House said on Sunday. The White House has long been critical of practices by U.S. companies that it views as avoiding tax responsibilities...

  • Obama seeks $215 million for 'precision medicine' Friday, 30 Jan 2015 | 6:00 AM ET
    President Barack Obama delivers the State of the Union address on January 20, 2015 in the House Chamber of the U.S. Capitol in Washington.

    President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.

  • Drugmakers get mysterious invites to White House Wednesday, 28 Jan 2015 | 5:06 PM ET
    President Barack Obama

    The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.

  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • HALFTIME FINAL TRADES 1/27/15 Tuesday, 27 Jan 2015 | 1:26 PM ET
  • Jan 27- Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S. drugmakers. Bristol-Myers, whose shares fell almost 2 percent in premarket trading, said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to...

  • Robert Califf, a top cardiologist and researcher, to oversee its drug, medical device and tobacco policy in what experts said is a coup for the FDA. "This is a great catch for the FDA," said Dr. Califf has run countless clinical studies, published more than 1,000 papers, served as an FDA adviser and has twice been interviewed as a potential FDA commissioner.

  • Ebola vaccine trials to begin in Liberia Thursday, 22 Jan 2015 | 3:45 PM ET
    Health workers don protective equipment at the Island Clinic in Monrovia, Liberia.

    A clinical trial of two experimental Ebola vaccines is expected to start in Liberia in the next couple of weeks, the NIH said.